Guideline for PET/CT imaging of neuroendocrine neoplasms with <sup>68</sup>Ga-DOTA-conjugated somatostatin receptor targeting peptides and <sup>18</sup>F-DOPA.
Abstract
<h4>Purpose & methods</h4>Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using <sup>68</sup>Ga-DOTA-conjugated peptides, as well as <sup>18</sup>F-DOPA imaging for various neuroendocrine neoplasms.<h4>Results & conclusion</h4>The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with <sup>68</sup>Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.